Abstract:PURPOSE:Novel Bayesian adaptive designs provide an effective way to improve clinical trial efficiency. These designs are superior to conventional methods, but implementing them can be challenging. The aim of this article was to describe what we learned while applying a novel Bayesian phase I-II design in a recent trial.METHODS:The primary goal of the trial was to optimize radiation therapy (RT) dose among three levels (low, standard, and high), given either with placebo (P) or an investigational agent (A), for treating locally advanced, radiation-naive pancreatic cancer, deemed appropriate for RT rather than surgery. Up to 48 patients were randomly assigned fairly between RT plus P and RT plus A, with RT dose-finding done within each arm using the late-onset efficacy-toxicity design on the basis of two coprimary end points, tumor response and dose-limiting toxicity, both evaluated at up to 90 days. The random assignment was blinded, but within each arm, unblinded RT doses were chosen adaptively using software developed within the institution.RESULTS:Implementing the design involved double-blind balance-restricted random assignment, real-time assessment of patient outcomes to evaluate the efficacy-toxicity trade-off for each RT dose in each arm to optimize each patient's RT dose adaptively, and transition from a single-center trial to a multicenter trial. We present lessons learned and illustrative documentation.CONCLUSION:Implementing novel Bayesian adaptive trial designs requires close collaborations between physicians, pharmacists, statisticians, data managers, and sponsors. The process is difficult but manageable and essential for efficient trial conduct. Close collaboration during trial conduct is a key component of any trial that includes real-time adaptive decision rules.

Adaptive Dose Modification for Phase I Clinical Trials

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

A Dose-Finding Design for Phase I Clinical Trials Based on Bayesian Stochastic Approximation

Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Sequential Continual Reassessment Method for Two-Dimensional Dose Finding.

Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

A Comparative Study of Adaptive Trial Designs for Dose Optimization.